NASDAQ:YMAB

Y-mAbs Therapeutics Competitors

$26.38
-2.11 (-7.41 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.14
Now: $26.38
$28.45
50-Day Range
$28.34
MA: $34.24
$42.73
52-Week Range
$26.14
Now: $26.38
$55.22
Volume616,328 shs
Average Volume297,563 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36

Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) Vs. SAGE, BHVN, HCM, EBS, ARNA, and TPTX

Should you be buying YMAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Y-mAbs Therapeutics, including Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), Arena Pharmaceuticals (ARNA), and Turning Point Therapeutics (TPTX).

Y-mAbs Therapeutics (NASDAQ:YMAB) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 4.8% of Sage Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Y-mAbs Therapeutics and Sage Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47
Sage Therapeutics$6.87 million651.04$-680,240,000.00($13.38)-5.73

Y-mAbs Therapeutics has higher earnings, but lower revenue than Sage Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Y-mAbs Therapeutics and Sage Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Sage Therapeutics08802.50

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, suggesting a potential upside of 120.41%. Sage Therapeutics has a consensus price target of $87.0625, suggesting a potential upside of 13.64%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Y-mAbs Therapeutics is more favorable than Sage Therapeutics.

Profitability

This table compares Y-mAbs Therapeutics and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Summary

Y-mAbs Therapeutics beats Sage Therapeutics on 7 of the 13 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Y-mAbs Therapeutics and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Y-mAbs Therapeutics and Biohaven Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Biohaven Pharmaceutical021002.83

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Biohaven Pharmaceutical has a consensus price target of $96.4545, indicating a potential upside of 39.00%. Given Y-mAbs Therapeutics' higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Biohaven Pharmaceutical.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Biohaven Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.36

Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Y-mAbs Therapeutics beats Biohaven Pharmaceutical on 7 of the 11 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Hutchison China MediTech and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Y-mAbs TherapeuticsN/A-74.98%-66.70%

Analyst Recommendations

This is a summary of recent ratings and price targets for Hutchison China MediTech and Y-mAbs Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Y-mAbs Therapeutics02602.75

Hutchison China MediTech presently has a consensus price target of $40.00, indicating a potential upside of 36.80%. Y-mAbs Therapeutics has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Given Y-mAbs Therapeutics' higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Hutchison China MediTech.

Risk and Volatility

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Valuation & Earnings

This table compares Hutchison China MediTech and Y-mAbs Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.77$-106,020,000.00($0.80)-36.55
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47

Y-mAbs Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Y-mAbs Therapeutics beats Hutchison China MediTech on 7 of the 12 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Emergent BioSolutions and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Y-mAbs TherapeuticsN/A-74.98%-66.70%

Valuation & Earnings

This table compares Emergent BioSolutions and Y-mAbs Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.73$54.50 million$2.9126.58
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47

Emergent BioSolutions has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Comparatively, 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Emergent BioSolutions and Y-mAbs Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Y-mAbs Therapeutics02602.75

Emergent BioSolutions presently has a consensus price target of $109.8333, indicating a potential upside of 42.00%. Y-mAbs Therapeutics has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Emergent BioSolutions.

Risk and Volatility

Emergent BioSolutions has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Y-mAbs Therapeutics on 8 of the 13 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Y-mAbs Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
Arena PharmaceuticalsN/A-33.17%-30.41%

Valuation & Earnings

This table compares Y-mAbs Therapeutics and Arena Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47
Arena Pharmaceuticals$806.43 million4.96$397.55 million$7.698.62

Arena Pharmaceuticals has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Y-mAbs Therapeutics and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Arena Pharmaceuticals001503.00

Y-mAbs Therapeutics presently has a consensus target price of $58.1429, indicating a potential upside of 120.41%. Arena Pharmaceuticals has a consensus target price of $91.80, indicating a potential upside of 38.48%. Given Y-mAbs Therapeutics' higher probable upside, equities analysts clearly believe Y-mAbs Therapeutics is more favorable than Arena Pharmaceuticals.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Summary

Arena Pharmaceuticals beats Y-mAbs Therapeutics on 8 of the 12 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Y-mAbs Therapeutics and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
Turning Point TherapeuticsN/A-23.81%-23.08%

Valuation & Earnings

This table compares Y-mAbs Therapeutics and Turning Point Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.47
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-26.40

Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Y-mAbs Therapeutics and Turning Point Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Turning Point Therapeutics00703.00

Y-mAbs Therapeutics presently has a consensus target price of $58.1429, indicating a potential upside of 120.41%. Turning Point Therapeutics has a consensus target price of $153.7143, indicating a potential upside of 94.70%. Given Y-mAbs Therapeutics' higher probable upside, equities analysts clearly believe Y-mAbs Therapeutics is more favorable than Turning Point Therapeutics.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Turning Point Therapeutics beats Y-mAbs Therapeutics on 6 of the 11 factors compared between the two stocks.


Y-mAbs Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.